Bladder Cancer

Table of Contents

  1. Overview and Epidemiology
  2. Risk Factors
  3. Pathology and Histologic Subtypes
  4. Staging and Classification
  5. Clinical Presentation and Symptoms
  6. Diagnosis and Workup
  7. Treatment: Non-Muscle-Invasive Bladder Cancer
  8. Treatment: Muscle-Invasive and Metastatic Bladder Cancer
  9. Prognosis and Surveillance
  10. Key Research Papers
  11. Featured Videos
  12. Connections

Overview and Epidemiology

Bladder cancer is the most common malignancy of the urinary tract and the fifth most common cancer overall in the United States, with approximately 83,000 new cases and 17,000 deaths estimated annually. It affects men about four times more often than women — a disparity driven partly by higher rates of tobacco use and occupational carcinogen exposure historically — though women often present at a later stage, contributing to comparatively worse stage-for-stage outcomes in some series.

The median age at diagnosis is approximately 73 years, making bladder cancer predominantly a disease of older adults. In global terms, the highest incidence rates occur in Southern and Western Europe, North America, and Egypt (where the squamous cell variant linked to Schistosoma haematobium remains endemic). In the United States, bladder cancer accounts for roughly 5% of all new cancer diagnoses in men.

A defining epidemiological feature is the extraordinarily high recurrence rate in non-muscle-invasive disease: approximately 50 to 70% of patients with stage Ta or T1 tumors develop a recurrence within five years of initial treatment, making bladder cancer the most expensive cancer to manage over a lifetime on a per-patient basis due to the intensive endoscopic and intravesical surveillance burden.

Back to Table of Contents

Risk Factors

Bladder cancer arises from a well-characterized set of chemical carcinogens that damage the urothelium — the transitional epithelial lining of the bladder, ureters, and renal pelvis — through prolonged mucosal contact during urinary excretion.

Tobacco Smoking

Cigarette smoking is the single most important modifiable risk factor, accounting for approximately 50% of all bladder cancer cases in Western countries. The risk is dose-dependent: current smokers have a two- to fourfold increased risk compared with never-smokers, and heavy smokers face even higher risk. The carcinogenic mechanism involves aromatic amines (4-aminobiphenyl, 2-naphthylamine) and nitrosamines in tobacco combustion products that are absorbed into the bloodstream, filtered by the kidneys, and excreted in concentrated urine — bathing the bladder epithelium for hours. Pipe and cigar smoking confer risk comparable to or slightly lower than cigarettes. Smoking cessation reduces risk over time but does not return it to baseline.

Occupational Carcinogen Exposure

Occupational exposure to aromatic amines — particularly benzidine, beta-naphthylamine, and 4-aminobiphenyl used in the dye, rubber, textile, leather, and aluminum industries — is the second major risk factor. Workers in these industries may have a latency period of 5 to 50 years between exposure and bladder cancer diagnosis. Industrial regulations enacted in many countries from the 1970s onward have reduced but not eliminated this risk. Hairdressers (hair dye exposure), truck drivers (diesel exhaust), and painters also face modestly elevated risk.

Cyclophosphamide and Acrolein

The alkylating chemotherapy agent cyclophosphamide is metabolized to acrolein, a highly reactive aldehyde that is excreted in the urine. Acrolein directly damages bladder epithelial DNA. Patients treated with cyclophosphamide for lymphoma or autoimmune conditions have a nine-fold increased risk of bladder cancer. Mesna (sodium 2-mercaptoethane sulfonate) is routinely administered with high-dose cyclophosphamide to neutralize urinary acrolein and reduce this risk.

Aristolochic Acid

Aristolochic acid, found in Aristolochia plants used in some traditional herbal medicines, causes a specific mutational signature (A:T to T:A transversions) in urothelial cells. It is the dominant cause of Balkan endemic nephropathy — a progressive tubulointerstitial nephropathy prevalent in rural areas of Serbia, Croatia, Bosnia, and Romania — and associated upper tract urothelial carcinoma (affecting the renal pelvis and ureter more than the bladder). Populations consuming grain contaminated with Aristolochia clematitis seeds bear the highest risk.

Schistosoma haematobium

Schistosoma haematobium (blood fluke) infestation causes chronic granulomatous inflammation and calcification of the bladder wall. This chronic inflammatory milieu promotes a distinct histological transformation to squamous cell carcinoma of the bladder — not the urothelial (transitional cell) carcinoma that predominates in Western countries. Schistosomal bladder cancer accounts for up to 30% of bladder cancers in endemic regions of sub-Saharan Africa and the Middle East (especially Egypt). Patients typically present at a younger age and with more advanced local disease than Western urothelial carcinoma patients.

Chronic Urinary Tract Infection and Bladder Stones

Recurrent bacterial urinary tract infections and bladder stones are associated with squamous cell carcinoma of the bladder through a similar mechanism of chronic mucosal irritation and inflammation. Patients requiring long-term indwelling urinary catheters (for spinal cord injury or neurogenic bladder) have a substantially elevated risk of squamous cell carcinoma at the bladder base. Chronic cystitis from any cause creates a low-grade mutagenic milieu that drives squamous metaplasia and eventual malignant transformation over decades.

Back to Table of Contents

Pathology and Histologic Subtypes

The vast majority — approximately 90% — of bladder cancers in Western countries are urothelial carcinoma (UC), also called transitional cell carcinoma (TCC), arising from the urothelium that lines the bladder, ureters, and renal pelvis. The remaining 10% includes squamous cell carcinoma, adenocarcinoma (including urachal adenocarcinoma originating from a urachal remnant at the dome), and rare entities such as small cell carcinoma and sarcoma.

Urothelial (Transitional Cell) Carcinoma

Urothelial carcinoma is subclassified by growth pattern and grade. Papillary urothelial carcinoma — the most common pattern — grows as finger-like fronds projecting into the bladder lumen from a fibrovascular stalk, and ranges from low-grade (well-differentiated, rarely invasive) to high-grade (poorly differentiated, high risk of invasion and progression). Flat urothelial carcinoma in situ (CIS) is a high-grade, flat lesion confined to the urothelium that lacks a papillary architecture. CIS appears grossly as a reddish, velvety mucosal patch on cystoscopy and is markedly dangerous despite its superficial confinement: it carries a 40 to 80% risk of progression to muscle-invasive disease without treatment, making it the most clinically significant non-invasive lesion. Patients with CIS often present with urgency and dysuria rather than hematuria, mimicking cystitis.

Grading

The 2004 WHO grading system (adopted by the International Society of Urological Pathology) classifies urothelial carcinoma as low-grade or high-grade based on nuclear atypia, architectural disorder, and mitotic activity. Low-grade papillary tumors have a low risk of progression and excellent long-term survival; high-grade tumors — including all CIS and most T1 tumors — have a high risk of progression to muscle-invasive disease requiring aggressive management. The older WHO 1973 grading system (grade 1, 2, 3) is still referenced in older literature.

Squamous Cell Carcinoma

Pure squamous cell carcinoma of the bladder accounts for roughly 3 to 5% of cases in Western countries but is the predominant type in schistosomiasis-endemic regions. It is typically muscle-invasive at presentation, keratinizing on histology, and carries a worse prognosis than urothelial carcinoma of equivalent stage. Squamous differentiation within an otherwise urothelial tumor is also common and does not change the classification to squamous cell carcinoma.

Adenocarcinoma

Adenocarcinoma of the bladder (less than 2% of cases) can arise de novo from glandular metaplasia, from urachal remnants at the dome (urachal adenocarcinoma — a distinct entity requiring surgical resection of the umbilicus and urachal tract en bloc), or as a metastasis from colorectal or prostate primaries. Adenocarcinoma is typically muscle-invasive at presentation and is generally treated with radical cystectomy; it does not respond well to conventional urothelial carcinoma regimens.

Back to Table of Contents

Staging and Classification

Bladder cancer is staged using the AJCC/TNM system, with a clinically critical distinction between non-muscle-invasive and muscle-invasive disease that determines the entire treatment strategy.

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Approximately 75% of newly diagnosed bladder cancers are non-muscle-invasive at presentation. This group encompasses three pathological stages:

Muscle-Invasive Bladder Cancer (MIBC)

Twenty-five percent of bladder cancers are muscle-invasive at diagnosis. MIBC stages include:

Risk Stratification for NMIBC

EAU (European Association of Urology) and AUA guidelines risk-stratify NMIBC into low, intermediate, and high risk based on tumor number, size, grade, stage, presence of CIS, and prior recurrence history. High-risk NMIBC (T1 high-grade, CIS, recurrent high-grade Ta, multiple/large high-grade tumors) carries the greatest risk of progression to MIBC and requires aggressive surveillance and intravesical therapy. Very-high-risk NMIBC (BCG-unresponsive disease, T1 high-grade with CIS) may warrant early radical cystectomy.

Back to Table of Contents

Clinical Presentation and Symptoms

The cardinal presenting feature of bladder cancer is painless gross hematuria — visibly blood-tinged urine — which occurs in 80 to 90% of patients at some point in their disease course. The hematuria is characteristically intermittent (may be present one day and absent for weeks), and its absence at the time of evaluation should never reassure the clinician when the history includes even a single episode of gross hematuria. Any episode of painless gross hematuria in an adult mandates cystoscopic evaluation to exclude bladder cancer, regardless of whether a benign cause (UTI, kidney stone) has been identified — the benign cause does not exclude concurrent malignancy.

Microscopic Hematuria

Asymptomatic microscopic hematuria (three or more red blood cells per high-power field on urinalysis) is a less specific but important finding. AUA guidelines recommend cystoscopy and upper tract imaging for adults over 35 years with asymptomatic microscopic hematuria, particularly when risk factors for bladder cancer are present. Microscopic hematuria is a much more common finding than bladder cancer — the positive predictive value is approximately 2 to 5% — but the consequences of missing a diagnosis justify a thorough workup.

Irritative Lower Urinary Tract Symptoms

Urgency, frequency, and dysuria in the absence of infection strongly suggest carcinoma in situ, which irritates the bladder mucosa diffusely and stimulates detrusor overactivity. Patients with these symptoms who have repeatedly negative urine cultures should undergo cystoscopy and urine cytology to exclude CIS. The term "treatment-resistant cystitis" in middle-aged adults warrants malignancy evaluation.

Advanced Disease Symptoms

Locally advanced bladder cancer can cause flank pain or hydronephrosis from ureteral obstruction at the trigone, lower extremity edema from pelvic lymph node involvement obstructing iliac veins, pelvic pain, and fistulae (vesico-vaginal or vesico-rectal in locally advanced T4 disease). Constitutional symptoms — weight loss, anorexia, fatigue — suggest metastatic disease. Bone pain points to skeletal metastases, which occur preferentially in the axial skeleton and proximal femur.

Back to Table of Contents

Diagnosis and Workup

The standard diagnostic workup for suspected bladder cancer proceeds from non-invasive to invasive modalities, with cystoscopy remaining the definitive diagnostic test for bladder tumors.

Cystoscopy

Cystoscopy — direct visual inspection of the bladder interior through a flexible or rigid endoscope — is the gold standard for detecting bladder tumors. It allows direct visualization of papillary tumors, flat CIS lesions, and abnormal mucosa, and permits directed biopsy. Flexible cystoscopy under local anesthesia is the standard office procedure for initial evaluation and surveillance. Rigid cystoscopy under regional or general anesthesia is used when therapeutic maneuvers (TURBT) are planned. Narrow-band imaging (NBI) and photodynamic diagnosis (blue-light cystoscopy with hexaminolevulinate, HAL) enhance detection of flat CIS lesions that may be missed under white light alone.

Transurethral Resection of Bladder Tumor (TURBT)

TURBT is simultaneously the primary diagnostic and therapeutic procedure for bladder tumors. The surgeon resects the visible tumor along with a deep biopsy of the underlying muscularis propria to determine depth of invasion. A complete, adequate TURBT — with muscularis propria included in the specimen — is essential for accurate staging. An incomplete TURBT that fails to sample muscle leads to understaging: approximately 20 to 40% of patients initially staged as T1 are found to have muscle-invasive disease on re-resection. AUA and EAU guidelines recommend re-staging TURBT within 4 to 6 weeks for all T1 high-grade tumors and for any initial TURBT specimen that did not include muscularis propria.

Urine Cytology and Molecular Markers

Voided urine cytology is highly specific (greater than 95%) for high-grade urothelial carcinoma, making it an excellent complementary test. Its sensitivity is low for low-grade tumors (approximately 20 to 30%), and cytology is therefore most useful for detecting CIS, which exfoliates highly atypical cells into the urine. Molecular urine tests (NMP22, BladderChek, UroVysion FISH, Cxbladder, Bladder EpiCheck) have been developed as surveillance adjuncts but have not replaced cystoscopy in standard guidelines. The Paris System for Reporting Urinary Cytology (2016) standardized cytology interpretation around "high-grade urothelial carcinoma" as the primary diagnostic category.

Upper Tract Imaging

CT urography — combining an unenhanced CT, a nephrographic phase, and an excretory/urographic phase — provides comprehensive imaging of the entire urothelial surface from the renal calyces to the bladder, and simultaneously evaluates for lymphadenopathy and distant metastases. It is the preferred upper tract imaging modality for hematuria workup in most guidelines. Upper tract urothelial carcinoma (UTUC) coexists with bladder cancer in approximately 2 to 4% of patients, and any bladder urothelial carcinoma should prompt upper tract evaluation. For patients with contrast contraindications, MR urography is an alternative.

Staging Imaging for MIBC

CT of the chest, abdomen, and pelvis with contrast is required for all muscle-invasive bladder cancers to assess lymph node involvement and distant metastases (most commonly lungs, liver, and bones). MRI pelvis provides superior soft-tissue detail for evaluating extravesical extension and is increasingly used for local staging. Bone scan or PET-CT is reserved for symptomatic patients or those with elevated alkaline phosphatase.

Back to Table of Contents

Treatment: Non-Muscle-Invasive Bladder Cancer

Treatment of NMIBC is based on complete endoscopic resection followed by risk-stratified intravesical therapy to reduce recurrence and progression, with cystoscopic surveillance maintained indefinitely.

Intravesical BCG Immunotherapy

Bacillus Calmette-Guérin (BCG) — the attenuated live bacterium derived from Mycobacterium bovis — is the most effective intravesical agent for high-risk NMIBC (CIS, high-grade T1, recurrent high-grade Ta). Instilled directly into the bladder through a urethral catheter, BCG induces a local Th1 inflammatory immune response that activates cytotoxic T lymphocytes and natural killer cells against urothelial tumor cells. The full BCG induction course consists of six weekly instillations. Maintenance BCG (three weekly instillations at 3, 6, 12, 18, 24, 30, and 36 months — the SWOG maintenance schedule) significantly reduces progression to muscle-invasive disease compared with induction alone. BCG side effects include irritative voiding symptoms (urgency, frequency, dysuria) in most patients, and rare but serious systemic BCG sepsis requiring anti-tuberculous therapy.

Intravesical Mitomycin-C and Chemotherapy

Intravesical mitomycin-C (MMC), an alkylating chemotherapy agent, is the standard alternative for low- and intermediate-risk NMIBC. A single immediate post-TURBT instillation of MMC within 6 hours of resection — before tumor cells can implant on the raw resection site — reduces recurrence risk by approximately 12 percentage points and is recommended for all low-grade papillary tumors unless bladder perforation is suspected. Maintenance MMC or gemcitabine is used for intermediate-risk disease when BCG is unavailable or contraindicated. Combined gemcitabine plus docetaxel intravesical therapy has shown activity in BCG-unresponsive NMIBC.

BCG-Unresponsive Disease

BCG-unresponsive NMIBC — defined as high-grade disease persisting or recurring within 6 months of adequate BCG therapy — represents a clinical challenge. Radical cystectomy has historically been the recommended standard, but many patients decline or are unfit for surgery. Pembrolizumab (anti-PD-1) received FDA approval in 2020 for BCG-unresponsive CIS based on the KEYNOTE-057 trial, demonstrating a 41% complete response rate. Nadofaragene firadenovec-vncg (an adenoviral interferon-alpha gene therapy), N-803 (IL-15 superagonist plus BCG), and intravesical oportuzumab monatox are among other FDA-approved or investigational options for this difficult subset.

Surveillance

All NMIBC patients require indefinite endoscopic surveillance given the high recurrence rate. AUA guidelines recommend cystoscopy every 3 months for the first 2 years following high-risk NMIBC, then every 6 months for years 3 and 4, and annually thereafter. Upper tract surveillance (CT urography) is also performed periodically for high-risk patients. Urine cytology may be added at surveillance visits, particularly when CIS is in the differential.

Back to Table of Contents

Treatment: Muscle-Invasive and Metastatic Bladder Cancer

Muscle-invasive bladder cancer requires systemic-level treatment strategies. The standard curative approach is radical cystectomy, though bladder-preservation trimodality therapy is an established alternative for carefully selected patients.

Neoadjuvant Cisplatin-Based Chemotherapy

Neoadjuvant chemotherapy (NAC) before radical cystectomy is the standard of care for cisplatin-eligible patients with clinical stage T2–T4a, N0–Nx MIBC. Two to four cycles of gemcitabine plus cisplatin (GC) or four cycles of MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) improve five-year overall survival by approximately 5 to 8 percentage points in pooled analyses — an absolute benefit that is considered meaningful in this disease. The most important reason to administer NAC is that patients tolerate chemotherapy better before surgery than after (when renal function may be compromised by the urinary diversion). Approximately 25 to 35% of patients who receive NAC achieve a pathological complete response (pCR, pT0) at cystectomy, which is associated with a markedly favorable prognosis.

Radical Cystectomy

Radical cystectomy — removal of the bladder, prostate and seminal vesicles (in men), or uterus, ovaries, anterior vaginal wall, and urethra (in women) — plus pelvic lymph node dissection is the gold-standard curative surgery for MIBC. An extended pelvic lymph node dissection (including presacral, common iliac, and obturator chains) is associated with improved staging accuracy and potentially improved survival. Urinary diversion after cystectomy may be incontinent (ileal conduit) or continent (orthotopic neobladder using detubularized ileum, or continent cutaneous diversion). Neobladder reconstruction allows voiding per urethra and is preferred by many patients when anatomically feasible. Robot-assisted laparoscopic radical cystectomy has been widely adopted but has not demonstrated superior oncologic outcomes compared to open surgery in the RAZOR randomized trial.

Bladder-Sparing Trimodality Therapy

Trimodality therapy (TMT) — maximal TURBT followed by concurrent chemoradiotherapy (typically 45–50.4 Gy with weekly cisplatin or twice-daily low-dose cisplatin/5-FU) — is the established bladder-preserving curative alternative for appropriately selected patients with solitary, resectable tumors without hydronephrosis or CIS. The BC2001 (gemcitabine/mitomycin sensitization) and other trials demonstrate approximately 70–80% bladder preservation with similar 5-year overall survival to cystectomy in selected patients. Patients who fail TMT (residual or recurrent invasive disease) may undergo salvage cystectomy.

Adjuvant Therapy

Adjuvant chemotherapy (gemcitabine-cisplatin) for pathologically high-risk features (pT3/T4 or pN+) after cystectomy is an option when NAC was not given. Adjuvant nivolumab (CheckMate 274 trial) demonstrated significantly improved disease-free survival for pT3/T4 or pN+ urothelial carcinoma after cystectomy and received FDA approval in 2021 for this indication. Erdafitinib, a selective FGFR inhibitor, is approved for FGFR3-mutated advanced urothelial carcinoma after platinum-containing chemotherapy.

First-Line Metastatic Treatment

For metastatic urothelial carcinoma, cisplatin-based chemotherapy (gemcitabine-cisplatin) remains a mainstay for cisplatin-eligible patients. Pembrolizumab or atezolizumab is used as first-line therapy for cisplatin-ineligible patients with PD-L1-high tumors. Most transformatively, the EV-302 (KEYNOTE-A39) phase 3 trial demonstrated that enfortumab vedotin plus pembrolizumab — an antibody-drug conjugate targeting Nectin-4 combined with anti-PD-1 — doubled median overall survival compared to platinum-based chemotherapy as first-line therapy for locally advanced or metastatic urothelial carcinoma, leading to FDA approval in December 2023 and a paradigm shift making this combination the new preferred first-line standard.

Back to Table of Contents

Prognosis and Surveillance

Prognosis in bladder cancer is strongly determined by stage and grade at diagnosis. For non-muscle-invasive disease, the 5-year cancer-specific survival exceeds 90% for low-grade Ta, approximately 80% for T1 high-grade managed with BCG, and approximately 60–70% for CIS with BCG maintenance. Progression to muscle-invasive disease occurs in approximately 15–20% of T1 high-grade and 50–60% of BCG-unresponsive CIS patients.

For muscle-invasive disease treated with radical cystectomy, 5-year overall survival rates are approximately 63–68% for pT2N0, 50–55% for pT3N0, 35–45% for pT4N0, and 20–35% for node-positive disease. Patients achieving pathological complete response after neoadjuvant chemotherapy have a 5-year survival approaching 85%. Median overall survival for metastatic disease with prior platinum-based therapy was historically approximately 6–9 months; with enfortumab vedotin plus pembrolizumab in the first-line setting, median overall survival extended to approximately 31 months in the EV-302 trial, representing the most significant survival improvement in metastatic urothelial carcinoma in decades.

Long-term surveillance after radical cystectomy includes upper tract imaging (CT urography), urethral wash cytology, liver function tests, and renal function assessment, as upper tract recurrences occur in 2–4% of patients and urethral recurrences in 5–10%. Patients with continent diversions and neobladders require additional metabolic monitoring for vitamin B12 deficiency, hyperchloremic metabolic acidosis, and urinary tract infections.

Back to Table of Contents

Key Research Papers

  1. Sylvester RJ et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables. Eur Urol. 2006.
    PMID: 16442208 — Landmark study developing the EORTC risk table scoring system for predicting 1- and 5-year recurrence and progression probabilities in individual NMIBC patients based on six clinical and pathological factors.
  2. Lamm DL et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000.
    PMID: 11025658 — SWOG randomized trial establishing that BCG maintenance therapy significantly reduces recurrence and is superior to induction-only BCG in high-risk NMIBC, defining the standard 3-year maintenance schedule.
  3. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005.
    PMID: 16029940 — Individual patient data meta-analysis of 11 randomized trials demonstrating a statistically significant 5% absolute improvement in overall survival with platinum-based neoadjuvant chemotherapy before cystectomy for MIBC.
  4. von der Maase H et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005.
    PMID: 16009957 — Long-term follow-up of the landmark randomized trial showing gemcitabine-cisplatin has equivalent efficacy to MVAC with a superior tolerability profile, establishing GC as the preferred first-line regimen for metastatic urothelial carcinoma.
  5. Powles T et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024.
    PMID: 38261050 — EV-302/KEYNOTE-A39 phase 3 trial demonstrating that enfortumab vedotin plus pembrolizumab approximately doubled progression-free and overall survival compared to platinum-based chemotherapy as first-line therapy for locally advanced or metastatic urothelial carcinoma.
  6. Bellmunt J et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017.
    PMID: 28212060 — KEYNOTE-045 phase 3 trial demonstrating superior overall survival of pembrolizumab versus investigator-choice chemotherapy in platinum-refractory metastatic urothelial carcinoma, establishing pembrolizumab as the second-line standard.
  7. James ND et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012.
    PMID: 22509093 — BC2001 randomized trial showing that adding fluorouracil and mitomycin-C to radiotherapy significantly improved locoregional disease-free survival in MIBC, supporting chemoradiotherapy as the standard bladder-preservation strategy.
  8. Babjuk M et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022.
    PMID: 35063386 — Updated EAU guidelines providing comprehensive evidence-based recommendations for risk stratification, TURBT technique, intravesical therapy selection, and surveillance protocols in NMIBC.
  9. Bajorin DF et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021.
    PMID: 33369355 — CheckMate 274 phase 3 trial demonstrating significantly improved disease-free survival with adjuvant nivolumab versus placebo after radical surgery in patients with high-risk MIBC or upper tract urothelial carcinoma, leading to FDA approval.
  10. Daneshmand S et al. Efficacy and safety of nadofaragene firadenovec for patients with high-risk, BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021.
    PMID: 34516119 — Pivotal trial leading to FDA approval of the first gene therapy for bladder cancer (nadofaragene firadenovec-vncg), demonstrating 53% complete response rate at 3 months in BCG-unresponsive CIS.
  11. Kamat AM et al. Bladder cancer. Lancet. 2016.
    PMID: 26784962 — Comprehensive Lancet seminar reviewing epidemiology, molecular pathogenesis, diagnosis, staging, treatment across all stages, and emerging therapies for bladder cancer.
  12. Witjes JA et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer. Eur Urol. 2020.
    PMID: 32107002 — Joint EAU-ESMO consensus recommendations for management of locally advanced, metastatic, and histological variant bladder cancers, addressing areas of clinical uncertainty and providing unified European expert guidance.

Additional PubMed searches: Bladder cancer treatment guidelines | BCG immunotherapy bladder cancer | Radical cystectomy outcomes | Enfortumab vedotin urothelial carcinoma

Back to Table of Contents

Back to Table of Contents

Connections

Back to Table of Contents